Mohsen Sheykhhasan, Joanna K.L. Wong and Alexander M. Seifalian* Pages 532 - 548 ( 17 )
The potential use of stem cell-based therapies for the repair and regeneration of various tissues and organs offers a paradigm shift in regenerative medicine. The use of either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC) in clinical situations is limited because of regulations and ethical considerations even though these cells are theoretically highly beneficial. While clinically, adipose-derived stem cells (ADSCs) are one of the most widely used types of stem cells used more than five years in clinically setting. It has many advantages including; yields a high number of ADSCs per volume of tissue, high rate of proliferation, anti-fibrotic, anti-apoptotic, anti-inflammation, immunomodulation, and paracrine mechanisms have been demonstrated in various preclinical studies. It is much easier to harvest compared with bone marrow stem cells. Results of clinical studies have demonstrated the potentials of ADSCs for stem cells therapy for a number of clinical disorders. The aim of this paper was to provide an update on the most recent developments of ADSCs, by highlighting the properties and features of ADSCs, critically discussing its clinical benefit and its clinical trials in treatment and regeneration. This is a multi-billion dollars industry with huge interest to clinician, academia and industries.
Adipose-derived stem cells, therapeutic medicine, wound lesions, respiratory disease, bone and cartilage diseases, crohn’s disease, neurological disease, kidney disease, heart diseases, urological dysfunctions, cosmetic and plastic surgery.
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Imperial College School of Medicine, Imperial College London, London, Nanotechnology and Regenerative Medicine Centre (Ltd), The London Innovation BioScience Centre, London